Genomic data trust: provenance requirements for precision medicine
Genomic data powers precision medicine, but fewer than 30% of clinical genomic datasets carry full provenance metadata. Without knowing where a variant call originated, how a sample was processed, and whether consent covers secondary AI use, precision medicine operates on assumptions rather than evidence. Genomic data trust requires provenance infrastructure that most health systems have not built.
A single whole-genome sequence generates roughly 200 gigabytes of raw data. By the time that data reaches a clinical decision, it has passed through sequencing instruments, bioinformatics pipelines, variant annotation databases, and interpretation software. At each step, metadata can be lost, altered, or never recorded. The result: clinicians act on genomic findings without a clear chain of custody for the data that produced them.
This is the genomic data trust problem. And it is the single largest barrier to scaling precision medicine beyond academic medical centers.
Why provenance is harder for genomic data than for other clinical data
Electronic health records track who entered a lab value and when. Genomic data has no equivalent. A variant call file (VCF) rarely records which version of the reference genome was used, which alignment algorithm processed the reads, or which filtering thresholds removed artifacts.
The problem compounds downstream. When genomic findings enter a patient's medical record, they often arrive as a PDF report from an external lab. The structured data behind that report, including quality scores, read depth, and allele frequencies, stays locked in the sequencing facility's internal systems.
Precision medicine data provenance requires tracking not just the final clinical assertion ("pathogenic variant in BRCA2") but every computational and human decision that produced it.
Who owns the genome, and who controls its reuse
Related searches reveal a persistent public concern: genetic privacy and who owns the genome. The answer varies by jurisdiction. Only a handful of U.S. states require explicit informed consent for genetic testing beyond the clinical encounter. Federal protections under GINA cover employment and health insurance discrimination but say nothing about life insurance, long-term care, or data licensing to third parties.
When genomic data enters AI training pipelines, existing consent frameworks often break down entirely. A patient who consented to diagnostic sequencing did not necessarily consent to their variant data training a pharmacogenomics model. Consent governance must be granular, versioned, and auditable. This is precisely the problem ConsentOS was designed to address, and why consent governance failures in healthcare remain a systemic risk.
What genomics AI data quality actually requires
Genomic AI models are only as reliable as their training data. A model trained on variants called with outdated annotation databases will produce outdated risk predictions. A model trained on sequencing data from a single ethnic population will underperform for everyone else.
Genomics AI data quality depends on at least four verifiable conditions:
Without structured answers to all four, a genomic dataset cannot be trusted for AI applications. The current ranking content focuses on data sharing and vendor security. Neither addresses the upstream problem: most genomic data lacks the metadata needed to evaluate its fitness for any secondary use.
Key statistics
The scale of the provenance gap is measurable:
Why genetic information should be private, and why privacy alone is insufficient
Genetic data is uniquely identifying. Unlike a credit card number, a genome cannot be changed after a breach. It also implicates biological relatives who never consented to any data collection. This is why genetic privacy consistently appears in public search behavior around this topic.
But privacy protections without provenance are incomplete. Encrypting a genomic file does not tell you whether the variant calls inside it were generated correctly. De-identifying a dataset does not confirm that the bioinformatics pipeline met clinical-grade standards. Privacy answers who can see the data. Provenance answers whether the data is worth seeing.
The chain of custody problem in health data applies to genomics with particular force because genomic data passes through more computational intermediaries than any other clinical data type. As we have written about extensively, provenance is the hardest dimension of data trust to get right.
Building genomic data trust with scoring infrastructure
SuperTruth's DTI Engine scores every health data record from 0 to 100 across eight dimensions. For genomic data, the Provenance dimension (25% weight) evaluates whether a record carries traceable lineage from sample collection through variant interpretation. The Consent dimension (20% weight) checks whether the consent scope covers the intended use, including AI model training.
This scoring approach converts abstract trust concerns into quantifiable, auditable metrics. A genomic dataset with a DTI score of 40 tells a research team exactly how much remediation work stands between raw data and reliable model input. A score of 85 signals readiness for regulatory-grade applications.
Precision medicine will not scale on faith. It will scale on infrastructure that makes genomic data trust measurable, enforceable, and specific to each record.
What needs to happen next
Health systems building precision medicine programs need three things before they deploy genomic AI: provenance metadata captured at the point of sequencing, consent governance that tracks permission scope through every downstream use, and a scoring framework that flags records unfit for clinical or research application.
The technology exists. The standards exist. What most organizations lack is the integration layer that ties provenance, consent, and quality into a single trust score per record.
That is what we built the DTI Engine to do.
To discuss how genomic data trust scoring applies to your precision medicine or research program, contact Louis Simeonidis, SVP Commercial Operations, at louis@supertruth.ai or (215) 918-4140.
Further reading:
Jason Alan Snyder
Co-founder of SuperTruth and Artists & Robots, and an inventor on the Data Trust Index patents. Twenty-plus years building technology inside Interpublic Group. He writes here nearly every day on data trust, provenance, and what AI should be allowed to act on, and publishes essays on his Substack.
About SuperTruth · LinkedIn · Substack · jasonalansnyder.com
See it in practice
DTI scores the record, not the patient.
8 dimensions. 0–100. Travels with every record permanently.